Lee Hambright
Stock Analyst at Bernstein
(2.65)
# 1,803
Out of 4,826 analysts
22
Total ratings
68.75%
Success rate
9.74%
Average return
Main Sectors:
Stocks Rated by Lee Hambright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDT Medtronic | Maintains: Outperform | $96 → $97 | $83.35 | +16.38% | 2 | Nov 20, 2024 | |
| PODD Insulet | Initiates: Outperform | $300 | $258.83 | +15.91% | 1 | Nov 6, 2024 | |
| TNDM Tandem Diabetes Care | Initiates: Outperform | $42 | $21.33 | +96.91% | 1 | Nov 6, 2024 | |
| DXCM DexCom | Maintains: Outperform | $82 → $86 | $80.25 | +7.17% | 2 | Oct 25, 2024 | |
| BSX Boston Scientific | Maintains: Outperform | $92 → $100 | $104.24 | -4.07% | 1 | Oct 24, 2024 | |
| ABT Abbott Laboratories | Maintains: Outperform | $133 → $138 | $132.60 | +4.07% | 2 | Oct 17, 2024 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $350 → $365 | $531.82 | -31.37% | 2 | May 31, 2023 | |
| ZBH Zimmer Biomet Holdings | Maintains: Market Perform | $136 → $152 | $90.48 | +67.99% | 1 | May 3, 2023 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $183 | $155.00 | +18.06% | 4 | Mar 16, 2022 | |
| SYK Stryker | Upgrades: Outperform | $288 → $295 | $381.56 | -22.69% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $132 → $135 | $75.20 | +79.52% | 3 | Mar 16, 2022 |
Medtronic
Nov 20, 2024
Maintains: Outperform
Price Target: $96 → $97
Current: $83.35
Upside: +16.38%
Insulet
Nov 6, 2024
Initiates: Outperform
Price Target: $300
Current: $258.83
Upside: +15.91%
Tandem Diabetes Care
Nov 6, 2024
Initiates: Outperform
Price Target: $42
Current: $21.33
Upside: +96.91%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $82 → $86
Current: $80.25
Upside: +7.17%
Boston Scientific
Oct 24, 2024
Maintains: Outperform
Price Target: $92 → $100
Current: $104.24
Upside: -4.07%
Abbott Laboratories
Oct 17, 2024
Maintains: Outperform
Price Target: $133 → $138
Current: $132.60
Upside: +4.07%
Intuitive Surgical
May 31, 2023
Maintains: Outperform
Price Target: $350 → $365
Current: $531.82
Upside: -31.37%
Zimmer Biomet Holdings
May 3, 2023
Maintains: Market Perform
Price Target: $136 → $152
Current: $90.48
Upside: +67.99%
Johnson & Johnson
Mar 16, 2022
Downgrades: Market Perform
Price Target: $183
Current: $155.00
Upside: +18.06%
Stryker
Mar 16, 2022
Upgrades: Outperform
Price Target: $288 → $295
Current: $381.56
Upside: -22.69%
Mar 16, 2022
Upgrades: Outperform
Price Target: $132 → $135
Current: $75.20
Upside: +79.52%